Selection of patients for sentinel lymph node biopsy in melanoma;Biopsia del ganglio centinela en el melanoma. Consideraciones para la selección de los pacientes

Medicina Clinica

Volumn 120, Issue 19, 2003, Pages 737-738

  Ferrándiz, Carlos ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERFERON;

CANCER LOCALIZATION; CLINICAL OBSERVATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL DECISION MAKING; MELANOMA; PATIENT SELECTION; PREDICTION; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 2442689893     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048064     Document Type: Editorial

References (18)

1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992;127:392-9.
2. Vidal-Sicart S, Piulachs J, Pons F, Castel T, Palou J, Herranz R. Detección del ganglio centinela con linfoescintografía y sonda intraoperatoria en pacientes con melanoma maligno. Med Clin (Barc) 1999;112:681-4.
3. Paradelo C, Fraile M, Ferrándiz C, Alastrue A, Bigatá X. La linfoescintografía en el estudio de los patrones de drenaje linfático en pacientes con melanoma maligno. Med Clin (Barc) 1999;113:281-4.
4. McMasters KM, Reitgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19:2851-5.
5. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass FG, et al. Molecular staging of malignant melanoma. JAMA 1998;280:1410-5.
6. Gershenwald JE, Thompson W, Mansfield PF, Lee JE. Multi-institutional melanoma lymphatic mapping experience: the prognosis value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
7. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;14:637-42.
8. Kirkwood J, Strawderman M, Ernstoff M, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
9. Kirkwood J, Ibrahim J, Sondak V, Richards J, Flaherty LE, Ernstoff MS, et al. High and low doses of interferon alpha-2b in high risk melanoma: first analysis of intergroup trial E 1690/S9111/c9190. J Clin Oncol 2000;18:2444-58.
10. Kirkwood J, Ibrahim J, Sosman JA, Sondak V, Agarwala SS, Ernstoff MS, et al. High-dose interferon alpha-2b significantly prolongs relapsed-free and overall survival are significantly prolonged by high-dose INF-alpha-2b (HD1) compared to vaccine GM2-KLH with QS21 (GMK Progenics) for high-risk resected melanoma: results of the intergroup Phase III study E1694/S9512/C503, 801. Ann Oncol 2000;11(Suppl 4):50.
11. Dubois RW, Sweeter SM, Atkins M, McMasters KM, Halbert R, Miller SJ, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol 2001;137:1217-24.
12. Schneebaum S, Briele HA, Walker MJ, Greager J, Wood DK, Ronan SG, et al. Cutaneous thick melanoma: prognosis and treatment Arch Surg 1987;122:707-11.
13. Balch CM, Soong S, Gershenwald JF, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
14. Morton DL, Thompson JF, Essner R, Elashioff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230:453-63.
15. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR, Leong SPL. Prediction of sentinel node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 1998;134:983-7.
16. Cascinelli N, Belli F, Santnami M, Fait V, Tetori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Progam experience. Ann Surg Oncol 2000;7:469-74.
17. Slingluff C, Vollmer R, Reitgen D, Seigler HF. Lethal thin malignant melanoma. Ann Surg 1988;208:150-61.
18. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-60.